Tectonic Therapeutic Inc (TECX) - News Archive

Tectonic Therapeutic, Inc. (NASDAQ: TECX) recently shared the complete results from Part A of their Phase 1b clinical trial of TX45, a potential treatment for Group 2 Pulmonary Hypertension in patients with Heart Failur...

Tectonic Therapeutics Makes Strides in Heart Failure Treatment with Promising TX45 Phase 1a Results On November 11, 2024, Tectonic Therapeutics, a clinical-stage biotechnology firm based in Watertown, Massachusetts, unv...

Tectonic Therapeutics, a clinical-stage biotechnology company, recently announced positive outcomes from the Phase 1a clinical trial of its lead investigational drug, TX45. The results underscore the drug s potential, s...